Equities

Zhejiang Cheng Yi Pharmaceutical Co Ltd

603811:SHH

Zhejiang Cheng Yi Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.21
  • Today's Change-0.08 / -1.27%
  • Shares traded3.92m
  • 1 Year change-46.33%
  • Beta0.9536
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments29421481
Total Receivables, Net979481
Total Inventory117111117
Prepaid expenses9.84196.79
Other current assets, total----1.92
Total current assets517437288
Property, plant & equipment, net1,003960745
Goodwill, net----2.42
Intangibles, net676870
Long term investments282235210
Note receivable - long term------
Other long term assets------
Total assets1,8931,7191,322
LIABILITIES
Accounts payable1195548
Accrued expenses362125
Notes payable/short-term debt1177696
Current portion long-term debt/capital leases9.66150.76
Other current liabilities, total619177
Total current liabilities343258247
Total long term debt31733661
Total debt444427158
Deferred income tax15183.11
Minority interest4.303.0513
Other liabilities, total211712
Total liabilities700631336
SHAREHOLDERS EQUITY
Common stock327234234
Additional paid-in capital143237238
Retained earnings (accumulated deficit)722617514
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.210.230.22
Total equity1,1921,088986
Total liabilities & shareholders' equity1,8931,7191,322
Total common shares outstanding327327327
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.